Use of recombinant factor VIIa in orthotopic liver transplant
Indian Journal of Anaesthesia, 2011 Pradeep Bhatia
doaj +2 more sources
The prophylactic use of recombinant factor VIIa in a patient with DeBakey type III aortic dissection -A case report- [PDF]
Korean Journal of Anesthesiology, 2011 Little is known about the prophylactic use of recombinant factor VIIa (rFVIIa) in patients undergoing surgery for a bleeding aorta employing cardiopulmonary bypass.
Wook Jong Kim +7 more
doaj +1 more source
Haematologica, 2015 Standard treatment for Glanzmann thrombasthenia, a severe inherited bleeding disorder, is platelet transfusion. Recombinant factor VIIa is reported to be effective in Glanzmann thrombasthenia with platelet antibodies and/or refractoriness to platelet ...
Man-Chiu Poon +5 more
doaj +1 more source
Induction of endothelial cell proliferation by recombinant and microparticle-tissue factor involves β1-integrin and extracellular signal regulated kinase activation [PDF]
, 2010 Objective: Increased levels of circulating tissue factor (TF) in the form of microparticles increase the risk of thrombosis. However, any direct influence of microparticle-associated TF on vascular endothelial cell proliferation is not known.
Collier, Mary E. W., Ettelaie, Camille
core +2 more sources
Factor VII deficiency-related recurrent hemarthrosis in a female child – When to suspect?
Iraqi Journal of Hematology, 2021 Recurrent hemarthrosis is a common entity in children. Although recurrent hemarthrosis most often associated with hemophilia (VIII or IX deficiency), but rarely it can be associated with factor VII deficiency (FVIID).
Siyaram Didel +4 more
doaj +1 more source
Entering new areas in known fields: recombinant fusion protein linking recombinant factor VIIa with recombinant albumin (rVIIa-FP) – advancing the journey [PDF]
, 2016 The novel fusion protein linking recombinant factor VIIa with recombinant albumin (rVIIa-FP) is designed to extend the half-life of recombinant factor VIIa (rFVIIa) and improve the care of hemophilia A or B patients with inhibitors.
Legrand, Michel R +2 more
core +1 more source
Inhibitors in Patients with Congenital Bleeding Disorders Other Than Hemophilia [PDF]
, 2017 The most worrying complication of replacement therapy for severe hemophilia A and B is currently the occurrence of inhibitory alloantibodies against infused factor VIII and factor IX, respectively.
Franchini, Massimo +6 more
core +1 more source
Journal of the Formosan Medical Association, 2006 Recombinant factor VIIa (rFVIIa) was developed for the treatment of bleeding in hemophilic patients with inhibitors. It has also been used to stop bleeding in nonhemophilic patients who fail to respond to conventional treatment.
Yu-Feng Wei +4 more
doaj +1 more source
C2238/αANP modulates apolipoprotein E through Egr-1/miR199a in vascular smooth muscle cells in vitro [PDF]
, 2015 Subjects carrying the T2238C ANP gene variant have a higher risk to suffer a stroke or myocardial infarction. The mechanisms through which T2238C/αANP exerts detrimental vascular effects need to be fully clarified.
Bianchi, Franca +9 more
core +1 more source
Spontaneous bleeding in a patient with malignant lymphoma: A case of acquired hemophilia [PDF]
, 2000 Background: Acquired hemophilia is a rare condition which can be associated with lymphoproliferative disease. Case Report: Eleven yea rs after the diagnosis of immunocytoma had been made, a 72-year-old man developed a high-titer factor VIII inhibitor. At
Brack, N. +5 more
core +1 more source